Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2023.1228436 Oncology Correction Corrigendum: Antiproliferative effects of the natural oxadiazine Nocuolin A are associated with impairment of mitochondrial oxidative phosphorylation SousaMaria Lígia 1 2 PretoMarco 2 VasconcelosVítor 1 LinderStig 3 4 UrbatzkaRalph 2 * 1Faculty of Sciences of University of Porto, Porto, Portugal 2Interdisciplinary Centre of Marine and Environmental Research, Porto, Portugal 3Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institute, Stockholm, Sweden 4Department of Medical and Health Sciences, Linköping University, Linköping, Sweden

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

*Correspondence: Ralph Urbatzka, rurbatzka@ciimar.up.pt

02 06 2023 2023 13 1228436 24 05 2023 25 05 2023 Copyright © 2023 Sousa, Preto, Vasconcelos, Linder and Urbatzka 2023 Sousa, Preto, Vasconcelos, Linder and Urbatzka

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Antiproliferative effects of the natural oxadiazine Nocuolin A are associated with impairment of mitochondrial oxidative phosphorylation by Sousa ML, Preto M, Vasconcelos V, Linder S and Urbatzka R (2019) Front. Oncol. 9:224. doi: 10.3389/fonc.2019.00224 natural products cyanobacteria spheroids colon cancer anti-cancer drugs mitochondria autophagy section-in-acceptance Pharmacology of Anti-Cancer Drugs

In the published article, a reference in the funding statement was erroneously omitted as published. Instead of:

This research was supported by the Structured Program of R&D&I INNOVMAR—Innovation and Sustainability in the Management and Exploitation of Marine Resources (reference NORTE-01-0145-FEDER-000035, Research Line NOVELMAR), funded by the Northern Regional Operational Program (NORTE2020) through the European Regional Development Fund (ERDF). The project was additionally supported the project CYANCAN—Uncovering the cyanobacterial chemical diversity: the search for novel anticancer compounds (reference PTDC/MEDQUI/30944/2017) co-financed by NORTE 2020, Portugal 2020, and the European Union through the ERDF, and by Foundation for Science and Technology through national funds. RU was supported by the FCT postdoc grant SFRH/BPD/112287/2015 and MS by the FCT PhD grant SFRH/BD/108314/2015.

It should be:

This research was supported by the Structured Program of R&D&I INNOVMAR—Innovation and Sustainability in the Management and Exploitation of Marine Resources (reference NORTE-01-0145-FEDER-000035, Research Line NOVELMAR), funded by the Northern Regional Operational Program (NORTE2020) through the European Regional Development Fund (ERDF). The project was additionally supported the project CYANCAN—Uncovering the cyanobacterial chemical diversity: the search for novel anticancer compounds (reference PTDC/MED-QUI/30944/2017 - NORTE-01-0145-FEDER-030944) co-financed by NORTE 2020, Portugal 2020, and the European Union through the ERDF, and by Foundation for Science and Technology through national funds.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.